Current indications for ACE inhibitors and HOPE for the future

American Journal of Managed Care

Volumn 8, Issue 5, 2002, Pages 478-490

  Burch, Stephanie ^a   Ou, Narith ^a  

^a Heartland Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; FOSINOPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; LISINOPRIL; LOSARTAN; MOEXIPRIL; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN; ZOFENOPRIL;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE CALCULATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIABETIC NEPHROPATHIES; ECONOMICS, PHARMACEUTICAL; EDUCATION, CONTINUING; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; UNITED STATES;

EID: 0036095129     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study
2. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
3. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
4. Effect of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
6. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
7. A comparison of enalapril with hydralazine/isosorbide dinitrate in the treatment of chronic congestive heart failure
8. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
9. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: The GISSI-3 trial
10. ISIS-4. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
11. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial
12. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
13. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
14. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
15. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease
16. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
17. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE)
18. Angiotensin II and the endocrine pancreas: Effects on islet blood flow and insulin secretion in rats
19. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update
20. Prevention of events with angiotensin-converting enzyme inhibition. (the PEACE study design)
21. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA)
22. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
23. Angiotensin-converting enzyme inhibition as anti-atherosclerotic therapy: No answer yet
24. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT)
25. Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM): Rationale and design
26. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
27. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients
28. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
29. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency
30. A long-term randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies
31. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
32. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison
33. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: A multicenter study
34. Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
35. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLD) pilot study
36. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
37. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - The Losartan Heart Failure Survival Study (Elite II)
38. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
39. A long-term, randomized clinical trial to evaluate the effects of ramipril on the evolution of renal function in chronic nephropathies
40. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?
41. The cost and cardioprotective effects of enalapril in hypertensive patients with left ventricular dysfunction
42. Economics and cost effectiveness in evaluating the value of cardiovascular therapies: ACE inhibitors in the management of congestive heart failure: Comparative economic data
43. Cost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction: Results from GISSI-3 trial
44. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction: Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance
45. An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study: Application to the United Kingdom
46. The impact of angiotensin-converting enzyme inhibitors on managed care: Economic, clinical, and humanistic outcomes
47. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting enzyme inhibitor therapy for diabetic nephropathy
48. The cost effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
49. Cost-effectiveness of captopril therapy after myocardial infarction
50. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization